Summary of Study ST002787
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001737. The data can be accessed directly via it's Project DOI: 10.21228/M85X48 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002787 |
| Study Title | Metabolomic analysis of gut metabolites in colorectal cancer patients: correlation with disease development and outcome |
| Study Summary | In this study, targeted metabolomic sequencing was performed on fecal samples from 35 colorectal cancer (CRC) patients, 37 colorectal adenoma patients (CRA), and 30 healthy controls (HC) to identify metabolite biomarkers. Orthogonal partial least squares discriminant analysis (OPLS-DA) was used to identify metabolomic features distinguishing the three groups. ROC analysis found that 9,10-diHOME, cholesterol CE (18:2), and lipoxinA4 distinguished CRC from HC with an AUC of 0.969. The study highlights the advantages and potential applications of using LC-MS for targeted metabolomic analysis. |
| Institute | Wuhan University of Science and Technology |
| Department | School of Medicine |
| Laboratory | Hubei Province Key Laboratory of Occupational Hazard Identification and Control |
| Last Name | Xie |
| First Name | Zhufu |
| Address | No.2 Huangjiahu Road, Hongshan District, Wuhan City, Hubei Province, China |
| xiezhufu2020@outlook.com | |
| Phone | 18171407470 |
| Submit Date | 2023-05-07 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML |
| Analysis Type Detail | LC-MS |
| Release Date | 2024-07-01 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO002887 |
| Collection Summary: | We prospectively collected fecal samples from patients who underwent colonoscopy and histopathological examination at the Department of Gastroenterology, Affiliated Tianyou Hospital, Wuhan University of Science and Technology, from January 2017 to December 2017. We divided the subjects into three groups: patients with colorectal adenocarcinoma (n=35) were classified into the colorectal cancer (CRC) group, patients with colorectal adenoma (n=37) were classified into the adenoma (CRA) group, and recruited patients without colorectal pathology (n=30) were recorded as the healthy control (HC) group. Participants who had taken antibiotics or microecological drugs within two months prior to enrollment were excluded, as were subjects with bowel infections, gastrointestinal symptoms, hypertension, heart disease, diabetes, or a history of colonoscopy, adjuvant radiotherapy, or surgical treatment prior to sampling. The study was approved by the hospital ethics committee, and all subjects provided informed consent. CRC patients were followed up, and their survival data were collected during the follow-up period. |
| Sample Type: | Feces |
